Sanofi completes closing for potential first-in-class vaccine against ExPEC

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis

Sanofi announces today completion of closing for its collaborative agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) (ExPEC9V). 

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease annually, worldwide. It is associated with increased hospitalizations, mortality and antimicrobial resistance resulting in significant healthcare and societal costs.3,4 

Thomas Triomphe, Executive Vice President, Vaccines, Sanofi, said: “At Sanofi, we believe in the power of partnership to deliver true innovation. In this case, we’re bringing together Janssen’s robust science and Sanofi’s worldwide manufacturing footprint and expertise in launching innovative vaccines. We look forward to delivering this potential first-in-class vaccine designed to help older adults around the world live longer, healthier lives.”

ExPEC9V is currently being assessed via the Phase 3 E.mbrace trial which continues to enroll patients.